Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/17734
Title: ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types.
Authors: Chüeh, Anderly C;Tse, Janson W T;Dickinson, Michael;Ioannidis, Paul;Jenkins, Laura;Togel, Lars;Tan, BeeShin;Luk, Ian;Davalos-Salas, Mercedes;Nightingale, Rebecca;Thompson, Matthew R;Williams, Bryan R G;Lessene, Guillaume;Lee, Erinna F;Fairlie, Walter D;Dhillon, Amardeep S;Mariadason, John M
Affiliation: Ludwig Institute for Cancer Research, Melbourne, Australia..
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Department of Medicine, University of Melbourne, Parkville, Victoria, Australia
Peter MacCallum Cancer Centre, Parkville, Victoria, Australia
School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia
Hudson Institute of Medical Research and Department of Molecular and Translational Sciences, Monash University, Clayton, Victoria
The Walter and Eliza Hall Institute, Parkville, Victoria, Australia
Department of Biochemistry and Genetics, La Trobe University, Bundoora, Victoria, Australia
Issue Date: 15-Sep-2017
EDate: 2017-07-13
Citation: Clinical cancer research 2017; 23(18): 5573-5584
Abstract: Purpose: Histone deacetylase inhibitors (HDACi) are epigenome-targeting small molecules approved for the treatment of cutaneous T-cell lymphoma and multiple myeloma. They have also demonstrated clinical activity in acute myelogenous leukemia, non-small cell lung cancer, and estrogen receptor-positive breast cancer, and trials are underway assessing their activity in combination regimens including immunotherapy. However, there is currently no clear strategy to reliably predict HDACi sensitivity. In colon cancer cells, apoptotic sensitivity to HDACi is associated with transcriptional induction of multiple immediate-early (IE) genes. Here, we examined whether this transcriptional response predicts HDACi sensitivity across tumor type and investigated the mechanism by which it triggers apoptosis.Experimental Design: Fifty cancer cell lines from diverse tumor types were screened to establish the correlation between apoptotic sensitivity, induction of IE genes, and components of the intrinsic apoptotic pathway.Results: We show that sensitivity to HDACi across tumor types is predicted by induction of the IE genes FOS, JUN, and ATF3, but that only ATF3 is required for HDACi-induced apoptosis. We further demonstrate that the proapoptotic function of ATF3 is mediated through direct transcriptional repression of the prosurvival factor BCL-XL (BCL2L1) These findings provided the rationale for dual inhibition of HDAC and BCL-XL, which we show strongly cooperate to overcome inherent resistance to HDACi across diverse tumor cell types.Conclusions: These findings explain the heterogeneous responses of tumor cells to HDACi-induced apoptosis and suggest a framework for predicting response and expanding their therapeutic use in multiple cancer types. Clin Cancer Res; 23(18); 5573-84. ©2017 AACR.
URI: http://ahro.austin.org.au/austinjspui/handle/1/17734
DOI: 10.1158/1078-0432.CCR-17-0466
PubMed URL: 28611196
ISSN: 1078-0432
Type: Journal Article
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.